Olema Oncology to Present New Data on OP-1250 at 2021 San Antonio Breast Cancer Symposium
November 22, 2021 07:30 ET
|
Olema Oncology
Interim pharmacokinetic, safety and tolerability, and preliminary efficacy data from Phase 1 dose escalation to be presented Company to host investor webcast at 8:30 a.m. ET on Wednesday, December 8,...
Olema Oncology Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 10, 2021 16:05 ET
|
Olema Oncology
Completed dose-escalation stage of Phase 1/2 clinical trial of OP-1250 in patients with metastatic, ER+ / HER2- breast cancerInterim safety, tolerability, pharmacokinetic and initial efficacy data...
Olema Oncology to Present at Two Upcoming Investor Conferences
November 09, 2021 07:30 ET
|
Olema Oncology
SAN FRANCISCO, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Announces Trials in Progress Poster on OP-1250 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 30, 2021 17:00 ET
|
Olema Oncology
SAN FRANCISCO, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Present Data on OP-1250 at the 2021 JCA-AACR Precision Cancer Medicine International Conference
September 09, 2021 07:30 ET
|
Olema Oncology
SAN FRANCISCO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Present at Morgan Stanley 19th Annual Global Healthcare Conference
August 30, 2021 16:05 ET
|
Olema Oncology
SAN FRANCISCO, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 10, 2021 16:05 ET
|
Olema Oncology
Presentation of preliminary Phase 1/2 dose-escalation data for OP-1250 in patients with metastatic, ER+ / HER2- breast cancer planned for Q4 2021Strong cash, cash equivalents and marketable securities...
Olema Oncology to Present at Canaccord Genuity 41st Annual Growth Conference
July 28, 2021 16:05 ET
|
Olema Oncology
SAN FRANCISCO, July 28, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology to Participate at the Jefferies 2021 Virtual Healthcare Conference
May 18, 2021 16:05 ET
|
Olema Oncology
SAN FRANCISCO, May 18, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery,...
Olema Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 11, 2021 16:05 ET
|
Olema Oncology
OP-1250 continues to advance in dose-escalation stage of Phase 1/2 clinical trial in patients with metastatic, ER+ / HER2- breast cancer; Initial data anticipated in 2H 2021Cash, cash equivalents, and...